FDA Approves Triplet Immunotherapy Combination for Multiple Myeloma
The FDA has approved elotuzumab (Empliciti; Bristol-Myers Squibb) for use in combination with pomalidomide and dexamethasone for the treatment of adults with multiple myeloma who received ≥2 previous therapies including lenalidomide and a proteasome inhibitor.
This approval is based on results from the open-label, phase 2 ELOQUENT-3 clinical trial, in which elotuzumab plus pomalidomide and dexamethasone led to improved survival and responses compared with pomalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.
In ELOQUENT-3, a total of 117 patients were randomized in a 1:1 ratio to receive elotuzumab plus pomalidomide and dexamethasone (n = 60) or pomalidomide plus dexamethasone (n = 57). Patients received the drugs in 28-day cycles until disease progression or unacceptable toxicity occurred. The primary end point was progression-free survival (PFS), and the secondary end point was overall response rate.
The triplet combination of elotuzumab plus pomalidomide and dexamethasone reduced the risk for disease progression by 46% (hazard ratio, 0.54; 95% confidence interval [CI], 0.34-0.86; P = .0078), with a median PFS of 10.25 months versus 4.67 months with pomalidomide plus dexamethasone alone after a minimum follow-up of 9.1 months.
Overall response rates were 53.3% (95% CI, 40.0-66.3) for patients who received elotuzumab plus pomalidomide and dexamethasone compared with 26.3% (n = 15; 95% CI, 15.5-39.7; P = .0029) for patients who received pomalidomide and dexamethasone alone. Very good partial responses or better were seen in 20% and 8.8% of patients, respectively.
“Today’s approval reinforces the importance of Immuno-Oncology in blood cancers and expands the role of Empliciti to address the needs of relapsed or refractory multiple myeloma patients,” said Joseph E. Eid, MD, Senior Vice President and Head, Global Medical Affairs, Bristol-Myers Squibb, in a press release.
Serious adverse reactions were reported in 22% of patients treated with elotuzumab plus pomalidomide and dexamethasone and 15% of patients who received pomalidomide and dexamethasone alone. Adverse events led to treatment discontinuation in 5% and 1.8% of patients, respectively.—Janelle Bradley


